MedTrace Logo

Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia

NCT03422640 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-07-16

No results posted yet for this study

Summary

This is open label single side study involvement 20 patient treated with Apremilast. Each enrolled patient may be evaluated at by a dermatologist using the Lichen Planopilaris Activity Index and Frontal Fibrosing Alopecia Index. Other measures include physician global assessment, dermatology quality of life and patients analogue score for pruritus. Pt will have visits at Week 0,2,4,8,12,16,20,24

Conditions

  • Frontal Fibrosing Alopecia

Interventions

DRUG

Apremilast

Open label treatment with apremilast

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Bellevue Dermatology

    lead OTHER

Principal Investigators

  • Clive Liu, MD · Bellevue Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2019-01-31
Completion
2019-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422640 on ClinicalTrials.gov